Objective The purpose of this study was to assess the glucose-lowering and lipid-modifying effects and safety profile of lobeglitazone a novel peroxisome proliferator-activated receptor- γ agonist compared to placebo like a monotherapy in patients with type 2 diabetes. included numerous glycemic guidelines lipid guidelines and security profile (ClinicalTrials.gov quantity “type”:”clinical-trial” attrs :”text”:”NCT01001611″ term_id :”NCT01001611″NCT01001611). Results… Continue reading Objective The purpose of this study was to assess the glucose-lowering